Medial EarlySign

Early Detection of Life-threatening Conditions

Health Tech & Life Sciences
Non Active, Oct 2025 ceased to operate

Company Overview

Snapshot

Founded in January 2009 by Ori Geva and Nir Kalkstein, Medial EarlySign operates with 11–50 employees. The company has raised $50M across two funding rounds from five investors. In July 2022, EarlySign announced a strategic collaboration agreement with Roche for an AI solution focused on the early detection of lung cancer.

Business overview

Medial EarlySign develops AI-driven machine learning solutions to enhance patient health outcomes, optimize diagnostics, and improve medication management. The company's advanced models derive actionable clinical insights from large datasets, identifying individuals at high risk for various conditions such as non-small cell lung cancer, lower GI disorders, diabetes progression, and chronic kidney disease. Operating within the Health Tech & Life Sciences sector, specifically Digital Healthcare, Medial EarlySign serves healthcare providers globally with its AI-based clinical predictive analytics.

Strategic signal

In July 2022, Medial EarlySign announced a strategic collaboration with Roche to develop an AI solution for the early detection of lung cancer. This partnership signals a significant validation of Medial EarlySign's AI capabilities within the oncology space and demonstrates a clear path toward commercialization and integration with major pharmaceutical players, indicating strong potential for market impact and patient care improvement.

Company Intelligence Q&A

What is Medial EarlySign's primary focus?
Medial EarlySign focuses on developing AI-driven machine learning solutions for the early detection of life-threatening conditions, aiming to improve patient outcomes and optimize healthcare processes.
When was Medial EarlySign founded?
Medial EarlySign was founded in January 2009.
What was a significant partnership for Medial EarlySign in 2022?
In July 2022, Medial EarlySign announced a strategic collaboration agreement with Roche to develop an AI solution for the early detection of lung cancer.
Which investors participated in Medial EarlySign's Series B funding round in March 2018?
In March 2018, Medial EarlySign received funding from investors including aMoon Fund.
What was a key recognition for Medial EarlySign in 2017?
In May 2017, Medial EarlySign was named a "Cool Vendor in AI for Healthcare" by the Gartner Research Group.

External links